John B Mccarty

Author:

John Lawton McCarty

ISBN #:

0806120894

Author:

John McCarty

ISBN #:

0306813017

Author:

John McCarty

ISBN #:

0306814293

Author:

John McCarty

ISBN #:

0312017103

Author:

John McCarty

ISBN #:

0312017111

Author:

John McCarty

ISBN #:

0312017847

Author:

John McCarty

ISBN #:

0312029586

Author:

John McCarty

ISBN #:

0312070462

US Patent:

7230012, Jun 12, 2007

Filed:

Jun 30, 2003

Appl. No.:

10/608077

Inventors:

Paul D'Angio - Basking Ridge NJ, US
John McCarty - Miami Springs FL, US

Assignee:

Celgene Corporation - Summit NJ

International Classification:

A61K 31/445
A61K 9/48

US Classification:

514323, 424451

Abstract:

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

US Patent:

20060216344, Sep 28, 2006

Filed:

Mar 21, 2006

Appl. No.:

11/384381

Inventors:

Paul D'Angio - Basking Ridge NJ, US
John McCarty - Miami Springs FL, US

International Classification:

A61K 31/454
A61K 9/48

US Classification:

424451000, 514323000

Abstract:

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable stereoisomers, prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating, managing, and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

US Patent:

20070071806, Mar 29, 2007

Filed:

Feb 24, 2004

Appl. No.:

10/545774

Inventors:

John McCarty - Miami Springs FL, US

International Classification:

A61K 38/22
A61K 38/12
A61K 9/12
A61K 31/727
A61K 31/675
A61K 31/663
A61K 31/60
A61K 31/485
A61K 31/48
A61K 31/4745
A61K 31/535
A61K 31/5377
A61K 31/522
A61K 31/515

US Classification:

424451000, 424464000, 424045000, 514165000, 514056000, 514535000, 514263310, 514282000, 514649000, 514290000, 514291000, 514235500, 514304000, 514009000, 514089000, 514102000, 514012000, 514573000, 514317000, 514192000, 514288000, 514270000, 514217000, 514342000

Abstract:

Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.

US Patent:

20080269347, Oct 30, 2008

Filed:

Sep 28, 2007

Appl. No.:

11/864234

Inventors:

Jon Bruss - Cincinnati OH, US
John McCarty - Miami Springs FL, US
Blair West - Miramar FL, US

International Classification:

A61K 31/135
A61P 37/08

US Classification:

514653

Abstract:

The present invention generally concerns an epinephrine formulation that has enhanced stability. In particular embodiments, the formulation is an injectable formulation. In specific aspects, the formulation comprises epinephrine, EDTA, and one or more of an antioxidant such as cysteine, citric acid, acetylcysteine, or thioglycerol. The formulations are suitable for any medical condition that is in need of epinephrine, although in specific embodiments the medical condition is anaphylaxis, asthma, or cardiac arrest.

US Patent:

20100119601, May 13, 2010

Filed:

Apr 10, 2008

Appl. No.:

12/595183

Inventors:

John A. McCarty - Miami Springs FL, US

Assignee:

PHARMACEUTICAL PRODUCTIONS INC. - Miami Springs FL

International Classification:

A61K 31/4045
A61K 9/20
A61K 9/14
A61K 31/56
A61P 25/28
A61P 35/00

US Classification:

424464, 424490, 514171, 514419

Abstract:

The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

US Patent:

20130028943, Jan 31, 2013

Filed:

Oct 3, 2012

Appl. No.:

13/633924

Inventors:

John A. McCARTY - Miami Springs FL, US

International Classification:

A61K 31/4045
A61P 25/28
B05D 5/00
A61P 25/00
A61P 39/06
A61K 9/14
A61P 35/00

US Classification:

424400, 514415, 427 214

Abstract:

The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

US Patent:

59520043, Sep 14, 1999

Filed:

Aug 28, 1995

Appl. No.:

8/424521

Inventors:

Edward Rudnic - No. Potomac MD
John McCarty - Biscayne Park FL
Beth Burnside - Silverspring MD
Charlotte McGuinness - Rockville MD
George Belenduik - Potomac MD

Assignee:

Shire Laboratories Inc. - Rockville MD

International Classification:

A61K 966
A61K 948

US Classification:

424455

Abstract:

A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.

US Patent:

51126168, May 12, 1992

Filed:

Oct 8, 1991

Appl. No.:

7/773183

Inventors:

John A. McCarty - Biscayne Park FL

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

A61K 920
A61K 4700

US Classification:

424435

Abstract:

A fast dissolving buccal tablet for administering a medicament includes the active ingredient, a lubricant and a water soluble sugar, such as sorbitol, combined such that the buccal tablet dissolves in about one minute.